Silence Therapeutics (LON:SLN) has hired Stuart Collinson as a non-executive director as Simon Sturge resigns to take up other business commitments.
Experienced Collinson, 55, has held senior management roles at GlaxoWellcome, now GlaxoSmithKline and Baxter International and was chairman, chief executive and president of previously listed Aurora Biosciences, which was acquired by Vertex Pharmaceuticals (NASDAQ:VRTX) in 2001.
He has held various positions in public and private life science companies in the US and Europe and is a partner of Forward Ventures, a biopharmaceutical venture capital fund.
Ali Mortazavi, the chief executive of Silence Therapeutics, said: "We are very pleased to welcome Stuart to our board, who brings with him extensive experience in the sector with a business development and M&A track record across the US and Europe."
Shares were unchanged at 137.875p.